Lil­ly diss­es Am­gen and Mi­rati as it de­buts new KRAS mol­e­cule

Eli Lil­ly is re­join­ing the KRAS hunt.

The In­di­anapo­lis Big Phar­ma re­vealed Thurs­day, in an ab­stract for AACR, that it has been work­ing on a new small mol­e­cule to tar­get the in­fa­mous onco­gene and are plan­ning to put it in­to Phase I lat­er this year. It marks Lil­ly’s first pub­lic for­ay in­to the field in near­ly a year, since it ditched its first mol­e­cule af­ter see­ing dan­ger­ous side ef­fects in five pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.